Cargando…

Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia

AIMS: To report the anatomic and functional outcomes of intravitreal ranibizumab in idiopathic parafoveal telangiectasia (IPT). MATERIAL AND METHODS: Four eyes of three patients were included in this interventional case series. One patient (two eyes) had bilateral IPT (type 2) and two patients (two...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouvas, Alexandros, Malamos, Panagiotis, Douvali, Maria, Ntouraki, Amalia, Markomichelakis, Nikos N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707419/
https://www.ncbi.nlm.nih.gov/pubmed/23861579
http://dx.doi.org/10.2147/OPTH.S44109
_version_ 1782276502020161536
author Rouvas, Alexandros
Malamos, Panagiotis
Douvali, Maria
Ntouraki, Amalia
Markomichelakis, Nikos N
author_facet Rouvas, Alexandros
Malamos, Panagiotis
Douvali, Maria
Ntouraki, Amalia
Markomichelakis, Nikos N
author_sort Rouvas, Alexandros
collection PubMed
description AIMS: To report the anatomic and functional outcomes of intravitreal ranibizumab in idiopathic parafoveal telangiectasia (IPT). MATERIAL AND METHODS: Four eyes of three patients were included in this interventional case series. One patient (two eyes) had bilateral IPT (type 2) and two patients (two eyes) had unilateral (type 1) IPT. Retreatment was scheduled in case of leakage persistence in combination with visual acuity (VA) deterioration. Fluorescein angiography and optical coherence tomography were performed together with a full ophthalmic examination at baseline, 1, 3, 6, 9, and 12 months after injection. RESULTS: One intravitreal injection of ranibizumab was performed in all four eyes. Complete cessation of leakage was documented postintervention in three eyes and partial cessation in one eye, followed by improvement of best corrected VA in one of them. In all eyes, structural changes of the photoreceptor layer were detected in tomography and were responsible for visual loss, which was in most cases, refractory to the applied therapy. CONCLUSION: Use of ranibizumab might be efficient in eliminating leakage activity in the macular region in patients with IPT. Nevertheless, improvement in VA was infrequent. Preexisting early photoreceptor alteration in IPT might render such patients unable to improve VA.
format Online
Article
Text
id pubmed-3707419
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37074192013-07-16 Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia Rouvas, Alexandros Malamos, Panagiotis Douvali, Maria Ntouraki, Amalia Markomichelakis, Nikos N Clin Ophthalmol Case Series AIMS: To report the anatomic and functional outcomes of intravitreal ranibizumab in idiopathic parafoveal telangiectasia (IPT). MATERIAL AND METHODS: Four eyes of three patients were included in this interventional case series. One patient (two eyes) had bilateral IPT (type 2) and two patients (two eyes) had unilateral (type 1) IPT. Retreatment was scheduled in case of leakage persistence in combination with visual acuity (VA) deterioration. Fluorescein angiography and optical coherence tomography were performed together with a full ophthalmic examination at baseline, 1, 3, 6, 9, and 12 months after injection. RESULTS: One intravitreal injection of ranibizumab was performed in all four eyes. Complete cessation of leakage was documented postintervention in three eyes and partial cessation in one eye, followed by improvement of best corrected VA in one of them. In all eyes, structural changes of the photoreceptor layer were detected in tomography and were responsible for visual loss, which was in most cases, refractory to the applied therapy. CONCLUSION: Use of ranibizumab might be efficient in eliminating leakage activity in the macular region in patients with IPT. Nevertheless, improvement in VA was infrequent. Preexisting early photoreceptor alteration in IPT might render such patients unable to improve VA. Dove Medical Press 2013 2013-07-05 /pmc/articles/PMC3707419/ /pubmed/23861579 http://dx.doi.org/10.2147/OPTH.S44109 Text en © 2013 Rouvas et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Series
Rouvas, Alexandros
Malamos, Panagiotis
Douvali, Maria
Ntouraki, Amalia
Markomichelakis, Nikos N
Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
title Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
title_full Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
title_fullStr Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
title_full_unstemmed Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
title_short Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
title_sort twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707419/
https://www.ncbi.nlm.nih.gov/pubmed/23861579
http://dx.doi.org/10.2147/OPTH.S44109
work_keys_str_mv AT rouvasalexandros twelvemonthsoffollowupafterintravitrealinjectionofranibizumabforthetreatmentofidiopathicparafovealtelangiectasia
AT malamospanagiotis twelvemonthsoffollowupafterintravitrealinjectionofranibizumabforthetreatmentofidiopathicparafovealtelangiectasia
AT douvalimaria twelvemonthsoffollowupafterintravitrealinjectionofranibizumabforthetreatmentofidiopathicparafovealtelangiectasia
AT ntourakiamalia twelvemonthsoffollowupafterintravitrealinjectionofranibizumabforthetreatmentofidiopathicparafovealtelangiectasia
AT markomichelakisnikosn twelvemonthsoffollowupafterintravitrealinjectionofranibizumabforthetreatmentofidiopathicparafovealtelangiectasia